GRI Bio vs Pliant Therapeutics
GRI and PLRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRI and PLRX compare
Pliant Therapeutics is the larger company, worth 12 times as much as GRI Bio ($48.2M against $4.0M).
GRI Bio scores higher on the StockData Score (6 against 3 for Pliant Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRI | PLRX |
|---|---|---|
| Size and price | ||
| Market cap | $4.0M | $48.2M |
| Share price | $1.83 | $0.778 |
| Change, 1 year | −96.2% | −52.0% |
| Change, 5 years | −100% | −94.8% |
| Beta (5Y) | 0.77 | 1.02 |
| Employees | 4 | 49 |
| StockData Score | ||
| Total score | 6 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× | 0.3× (better) |
| FCF yield | – | −147% |
| Profitability | ||
| Return on equity | −142% | −50.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −102.5× |
| Current ratio | 10.30 (better) | 9.90 |
| Altman Z-score | −6.35 (better) | −6.74 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.3% | 77.7% |
| Held by insiders | 26.2% | 13.0% |
| Insider net buying, 12 months | – | −$164K |
| Short interest, % of float | 4.1% | 9.1% |
Go deeper
- GRI stock overview
- GRI income statement
- GRI valuation and score
- PLRX stock overview
- PLRX income statement
- PLRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.